Table 2 Baseline characteristics of survivors and non-survivors (28-day hospital outcomes).

From: Interfering with USP50 expression inhibits macrophage pyroptosis in sepsis-induced acute lung injury by degrading NLRP3 protein

 

Survival(N = 26)

Non-survivors (N = 22)

p

Gender(male,%)

14(53.85%)

10(45.45%)

0.566

Ages (years), mean ± SD

43.85 ± 11.36

42.36 ± 12.11

0.411

Pre-existing comorbidities

 COPD, n(%)

4(15.38%)

0(0%)

0.057

 CAD, n(%)

1(3.85%)

2(9.09%)

0.459

 Hypertension, n(%)

6(23.08%)

17(77.27%)

< 0.001

 CKD, n(%)

3(11.54%)

0(0%)

0.103

 Liver disease, n(%)

3(11.54%)

1(4.55%)

0.387

 Diabetes, n(%)

6(23.08%)

0(0%)

0.017

 Obesity, n(%)

3(11.54%)

2(9.09%)

0.784

Pathogen

 Gram-positive bacteria, n(%)

6(23.08%)

3(13.64%)

0.409

 Gram-negative bacteria, n(%)

2(7.69%)

7(31.82%)

0.035

 Virus, n(%)

5(19.23%)

5(22.73%)

0.769

 Fungus, n(%)

4(15.38%)

1(4.55%)

0.225

 Other pathogens, n(%)

6(23.08%)

2(9.09%)

0.200

 Undetected, n(%)

3(11.54%)

4(18.18%)

0.520

 USP50

1.92 ± 0.25

2.31 ± 0.30

< 0.001

  1. COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; CKD, chronic kidney disease.
Back to article page